Logo image of BDTX

BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Fundamental Analysis

NASDAQ:BDTX - US09203E1055 - Common Stock

2.92 USD
+0.21 (+7.75%)
Last: 8/22/2025, 8:00:02 PM
2.93 USD
+0.01 (+0.34%)
Pre-Market: 8/25/2025, 8:31:54 AM
Fundamental Rating

4

BDTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. While BDTX has a great health rating, its profitability is only average at the moment. BDTX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year BDTX was profitable.
BDTX had a positive operating cash flow in the past year.
BDTX had negative earnings in each of the past 5 years.
BDTX had a negative operating cash flow in each of the past 5 years.
BDTX Yearly Net Income VS EBIT VS OCF VS FCFBDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

BDTX has a Return On Assets of 8.68%. This is amongst the best in the industry. BDTX outperforms 93.05% of its industry peers.
Looking at the Return On Equity, with a value of 10.89%, BDTX belongs to the top of the industry, outperforming 93.05% of the companies in the same industry.
BDTX has a Return On Invested Capital of 2.48%. This is amongst the best in the industry. BDTX outperforms 91.41% of its industry peers.
Industry RankSector Rank
ROA 8.68%
ROE 10.89%
ROIC 2.48%
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
BDTX Yearly ROA, ROE, ROICBDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

BDTX has a better Profit Margin (20.63%) than 94.70% of its industry peers.
BDTX's Operating Margin of 6.72% is amongst the best of the industry. BDTX outperforms 91.59% of its industry peers.
Industry RankSector Rank
OM 6.72%
PM (TTM) 20.63%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDTX Yearly Profit, Operating, Gross MarginsBDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, BDTX has more shares outstanding
Compared to 5 years ago, BDTX has more shares outstanding
There is no outstanding debt for BDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BDTX Yearly Shares OutstandingBDTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BDTX Yearly Total Debt VS Total AssetsBDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

BDTX has an Altman-Z score of 0.69. This is a bad value and indicates that BDTX is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.69, BDTX is doing good in the industry, outperforming 62.71% of the companies in the same industry.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 0.69
ROIC/WACCN/A
WACCN/A
BDTX Yearly LT Debt VS Equity VS FCFBDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

BDTX has a Current Ratio of 8.73. This indicates that BDTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BDTX (8.73) is better than 76.42% of its industry peers.
A Quick Ratio of 8.73 indicates that BDTX has no problem at all paying its short term obligations.
BDTX's Quick ratio of 8.73 is fine compared to the rest of the industry. BDTX outperforms 76.42% of its industry peers.
Industry RankSector Rank
Current Ratio 8.73
Quick Ratio 8.73
BDTX Yearly Current Assets VS Current LiabilitesBDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 115.33% over the past year.
EPS 1Y (TTM)115.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BDTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y125.03%
EPS Next 2Y14.77%
EPS Next 3Y7.23%
EPS Next 5Y15.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDTX Yearly Revenue VS EstimatesBDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
BDTX Yearly EPS VS EstimatesBDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.70 indicates a correct valuation of BDTX.
Compared to the rest of the industry, the Price/Earnings ratio of BDTX indicates a rather cheap valuation: BDTX is cheaper than 96.53% of the companies listed in the same industry.
BDTX is valuated cheaply when we compare the Price/Earnings ratio to 27.24, which is the current average of the S&P500 Index.
BDTX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 12.7
Fwd PE N/A
BDTX Price Earnings VS Forward Price EarningsBDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

98.54% of the companies in the same industry are more expensive than BDTX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.3
EV/EBITDA -17.71
BDTX Per share dataBDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

BDTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2Y14.77%
EPS Next 3Y7.23%

More info and screens

0

5. Dividend

5.1 Amount

BDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLACK DIAMOND THERAPEUTICS I

NASDAQ:BDTX (8/22/2025, 8:00:02 PM)

Premarket: 2.93 +0.01 (+0.34%)

2.92

+0.21 (+7.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners83.34%
Inst Owner Change-7.04%
Ins Owners0.59%
Ins Owner Change-65.01%
Market Cap166.26M
Analysts85.45
Price Target10.46 (258.22%)
Short Float %11.51%
Short Ratio5.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2222.91%
Min EPS beat(2)24.48%
Max EPS beat(2)4421.34%
EPS beat(4)4
Avg EPS beat(4)1121.29%
Min EPS beat(4)12.77%
Max EPS beat(4)4421.34%
EPS beat(8)8
Avg EPS beat(8)569.11%
EPS beat(12)12
Avg EPS beat(12)381.81%
EPS beat(16)16
Avg EPS beat(16)289.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.65%
PT rev (3m)-21.15%
EPS NQ rev (1m)4.25%
EPS NQ rev (3m)26.96%
EPS NY rev (1m)28.09%
EPS NY rev (3m)144.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)300%
Valuation
Industry RankSector Rank
PE 12.7
Fwd PE N/A
P/S 2.38
P/FCF 9.3
P/OCF 9.3
P/B 1.25
P/tB 1.25
EV/EBITDA -17.71
EPS(TTM)0.23
EY7.88%
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)0.31
FCFY10.75%
OCF(TTM)0.31
OCFY10.75%
SpS1.23
BVpS2.33
TBVpS2.33
PEG (NY)0.1
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.68%
ROE 10.89%
ROCE 3.15%
ROIC 2.48%
ROICexc 55.06%
ROICexgc 55.06%
OM 6.72%
PM (TTM) 20.63%
GM N/A
FCFM 25.53%
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 353.99%
Profit Quality 123.78%
Current Ratio 8.73
Quick Ratio 8.73
Altman-Z 0.69
F-Score9
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.94%
Cap/Depr(5y)323.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.22%
EPS Next Y125.03%
EPS Next 2Y14.77%
EPS Next 3Y7.23%
EPS Next 5Y15.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.95%
EBIT Next 3Y-0.19%
EBIT Next 5Y2.75%
FCF growth 1Y124.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y124.55%
OCF growth 3YN/A
OCF growth 5YN/A